Lieu de naissance
TAKHAR
Langues
İNGİLİZCE
Domaines d’intérêt médical
- Cancers du sein
- du poumon
- du côlon
- du rectum
- de la tête et du cou
- de la peau
- sarcomes
- du cerveau
- des testicules
- de l'estomac
- du foie et des voies biliaires
- des os
À la une
Né en 1984, le Dr Jamshid Hamdard a obtenu son diplôme de médecine avec mention à la Faculté de médecine d'Istanbul en 2011. Il a complété sa formation par une spécialisation en médecine interne à l'Université Bezmialem Vakıf en 2016 et sa surspécialisation en oncologie médicale à l'Université Medipol en 2023.
Tout au long de sa carrière, il a manifesté un vif intérêt pour la recherche clinique, participant comme investigateur principal et associé à de nombreuses études internationales de phase 3, notamment sur les cancers du sein et du poumon. Le Dr Hamdard a enrichi son expertise académique avec plus de 27 articles publiés dans des revues internationales à comité de lecture. Hamdard poursuit ses activités universitaires et cliniques à l'Université Medipol d'Istanbul depuis 2023.
Expériences
2016
Medipol Mega Hastaneler Kompleksi
2016
Özel Medipol Mega Hastaneler Kompleksi
Éducation
2023
İstanbul Medipol Üniversitesi, Tıbbi Onkoloji
2016
İstanbul Bezmialem Vakıf Üniversitesi, İç Hastalıkları
2016
Bezmialem Vakıf Üniversitesi, İç Hastalıkları
2011
İstanbul Üniversitesi, İstanbul Tıp Fakültesi
2011
İstanbul Üniversitesi, Tıp Fakültesi
Publications
Uluslararası Hakemli Dergilerde Yayınlanan Makaleler
1. Acute phosphate nephropathy due to use of phosphorous enema: Case report International Journal of Urology and Nephrology Vol. 2 (2), pp. 052-054, August, 2014
2. Do We Really Treat Essential Thrombocythemia? A Clinical Trial Of 148 Patients With ET. Leukemia Research 38:S53 · October 2014
3. Comparison of tomographic and colonoscopic diagnoses in the presence of colonic wall thickening. International Journal Of Clinical And Experimental Medicine 6(90) · December 2014
4. A rare cause of duodenal obstruction: Superior mesenteric artery syndrome. Int J Case Rep Images 2015;6(12):783–785
5. Protective Effect Of Dexpanthenol Against Nephrotoxic Effect Of Amikacin: An Experimental Study. Conference Paper In Nephrology Dialysis Transplantation · May 2015
6. Acute Renal Failure due to Leukaemic Infiltration in Chronic Lymphocytic Leukaemia. Case Reports In Medicine 2015:1-3 July 2015
7. Reduced bone resorption and increased bone mineral density in women with restless legs syndrome. Neurology · February 2016 8. CD40 ligand and P-selectin in heterozygous Beta-thalassemia. Journal of the Pakistan Medical Association 66(6):699-704 · June 2016
8. CD40 ligand and P-selectin in heterozygous Beta-thalassemia. Journal of the Pakistan Medical Association 66(6):699-704 · June 2016
9. Relationship between the poor glycemic control and risk factors, life style and complications. Biomedical Research (2017) Volume 28, Issue 4
10. Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy. Oncol Res Treat. 2019;42(4):209-216. doi: 10.1159/000496746. Epub 2019 Mar 14
11. Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade. J Oncol Pharm Pract. 2019 Sep;25(6):1526-1530. doi: 10.1177/1078155218792672. Epub 2018 Aug 19
12. Major and minor salivary gland cancers: A multicenter retrospective study. Head Neck 2023 Jul;45(7):1643-1653. doi: 10.1002/hed.27376. Epub 2023 Apr 21.
13. Interferon Induced Focal Segmental Glomerulosclerosis Case Rep Nephrol 2016;2016:6967378. doi: 10.1155/2016/6967378. Epub 2016 Oct 26.
14. Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence. Breast J. 2021 Jan;27(1):56-57. doi: 10.1111/tbj.14091. Epub 2020 Oct 18.
15. Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib Pulmonology. 2022 Dec 21;S2531-0437(22)002641. doi:10.1016/j.pulmoe.2022.11.006. Online ahead of print.
16. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer Breast Care (Basel). 2022 Oct;17(5):470-479. doi: 10.1159/000524446. Epub 2022 May 3.
17. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer Medicine (Baltimore). 2021 Nov 5;100(44):e27712. doi: 10.1097/MD.0000000000027712.
18. The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment Colorectal Dis. 2021 Jan;23(1):206-212. doi: 10.1111/codi.15389. Epub 2020 Oct 20.
19. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21.
20. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data. J Gastrointest Cancer. 2023 Jun 22. doi: 10.1007/s12029-023-00953-0. Online ahead of print.
21. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy Medicine (Baltimore). 2023 Apr 14;102(15):e33432. doi: 10.1097/MD.0000000000033432.
22. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey. J BUON. 2021 Sep-Oct;26(5):1908-1917.
Ulusal Hakemli Dergilerde Yayınlanan Makaleler
1. An Unusual Case of Cushing’s Syndrome: Coexistence of Functional Pituitary and Adrenal Adenoma. DOI: 10.4274/haseki.3073 Med Bull Haseki 2017;55:61-3
Adhésions
Association turque d’oncologie médicale, Association médicale turque, Ordre des médecins d’Istanbul.
Activités scientifiques
*27 articles publiés dans des revues internationales à comité de lecture (SCI, SCI-E)
*6 présentations de cas publiées dans des revues internationales
*12 articles publiés dans des revues nationales à comité de lecture (TR-DİZİN)
*13 communications orales présentées lors de congrès scientifiques internationaux et nationaux
*15 présentations par affiche présentées lors de congrès scientifiques internationaux et nationaux
*3 chapitres d’ouvrages nationaux
*Nombreux essais cliniques internationaux de phase 2 et de phase 3 (investigateur principal et associé)